Sagimet Biosciences Inc. (NASDAQ:SGMT) Stock Has Consensus Target Price of $26.07

Sagimet Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Sagimet Biosciences a “Moderate Buy” consensus: nine of 11 covering brokerages rate the stock a buy, while two recommend selling. Their average 12-month price target is $26.07.
  • Analyst views include Oppenheimer raising its target to $38 and maintaining an outperform rating, while HC Wainwright set a $29 target with a buy rating.
  • Sagimet reported a quarterly loss of $0.31 per share, missing the $0.26 loss analysts expected. Institutional investors and hedge funds own 87.86% of the stock.
  • Five stocks we like better than Sagimet Biosciences.

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and nine have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $26.07.

SGMT has been the subject of a number of analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Sagimet Biosciences in a research report on Thursday, October 15th. Oppenheimer lifted their target price on shares of Sagimet Biosciences from $33.00 to $38.00 and gave the company an "outperform" rating in a report on Thursday, October 1st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Sagimet Biosciences in a research note on Thursday, October 1st. HC Wainwright reissued a "buy" rating and set a $29.00 price target on shares of Sagimet Biosciences in a report on Monday, October 5th. Finally, Citigroup restated a "market outperform" rating on shares of Sagimet Biosciences in a research report on Friday.

Check Out Our Latest Report on SGMT

Institutional Investors Weigh In On Sagimet Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Entropy Technologies LP purchased a new stake in shares of Sagimet Biosciences in the third quarter valued at about $182,000. AWM Investment Company Inc. grew its stake in Sagimet Biosciences by 275.0% during the 3rd quarter. AWM Investment Company Inc. now owns 300,000 shares of the company's stock valued at $2,964,000 after purchasing an additional 220,000 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Sagimet Biosciences in the 3rd quarter worth approximately $7,433,000. Empowered Funds LLC bought a new position in Sagimet Biosciences during the 3rd quarter worth $328,000. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Sagimet Biosciences in the third quarter valued at approximately $4,662,000. 87.86% of the stock is currently owned by institutional investors and hedge funds.

Sagimet Biosciences Stock Performance

Shares of NASDAQ:SGMT opened at $10.13 on Friday. The company has a 50-day simple moving average of $9.86 and a 200-day simple moving average of $7.71. Sagimet Biosciences has a one year low of $4.50 and a one year high of $11.45. The stock has a market capitalization of $629.68 million, a price-to-earnings ratio of -8.51 and a beta of 3.43.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.05). As a group, research analysts forecast that Sagimet Biosciences will post -1.14 EPS for the current fiscal year.

About Sagimet Biosciences

(Get Free Report)

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body's production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.

Recommended Stories

Analyst Recommendations for Sagimet Biosciences (NASDAQ:SGMT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sagimet Biosciences Right Now?

Before you consider Sagimet Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sagimet Biosciences wasn't on the list.

While Sagimet Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines